Biogen Inc vs Digital Realty Trust, Inc. — how do they compare? Biogen Inc trades at $204.39 (market cap $30.13B), while Digital Realty Trust, Inc. trades at $195.75 (market cap $70.61B). The key difference: Digital Realty Trust, Inc. is far larger — about 2.3× Biogen Inc's market cap, and Digital Realty Trust, Inc. pays a 2.56% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DLR | |
|---|---|---|
Market Cap | $30.13B | $70.61B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $203.91 |
52-Week Low | $128.93 | $147.93 |
Enterprise Value | $37.20B | $89.32B |
Dividend Yield | — | 2.56% |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Digital Realty (DLR) trades at $191.3, down 1.29% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates and raising full-year guidance, driven by record leasing and robust AI-driven data center demand. Revenue grew to $6.11B in 2025, with net income margin at 11.8%, though valuation ratios like P/E of 241.53 appear elevated. A dividend of $1.22 per share was declared for H1 2026.
DLR's outlook is positive due to strong AI infrastructure demand and raised guidance, but high valuation and significant capital expenditures pose risks. Analyst consensus is bullish with a $216.56 price target, though investors should monitor execution on growth targets and debt levels amid expanding investments.
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →